Q-omics provides the consensus-scored RNY1P12 profile across patient tissues and cancer cell-line models. RNY1P12 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, RNY1P12 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, RNY1P12 RNA expression shows 8,701 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SARC, THCA, and THYM as cancer lineages where RNY1P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY1P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY1P12 survival associations across molecular data types. RNY1P12 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY1P12 RNA expression–survival associations across cancer types. High RNY1P12 expression shows unfavorable associations in SARC, READ, KICH and PCPG, but favorable associations in LAML and STAD. The SARC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for RNY1P12 RNA expression.
This table summarizes RNY1P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNY1P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY1P12 shows lower tumor expression in THCA, BRCA, LUAD and KIRP and higher tumor expression in KIRC and STAD. The THCA box plot shows higher RNY1P12 RNA expression in normal versus tumor tissue (log2 FC = −0.270, t-test p = .004).
This table shows molecular features associated with RNY1P12 in patient tissues and cancer cell lines. In patient samples, RNY1P12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
